Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook GlobeNewswire January 09, 2026 Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric

iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference

— Participation underscores growing excitement around company’s momentum and potential in precision oncology iOnctura, a clinical-stage biopharmaceutical company developing precision oral small molecules for neglected and hard-to-treat cancers, today announces that its Chief Executive Officer, Catherine Pickering, will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco,

Rise Gold Announces Delay in Trial Schedule

Grass Valley, California–(Newsfile Corp. – January 9, 2026) – In its September 16, 2025 press release, Rise Gold Corp. (CSE: RISE) (OTCQB: RYES) (the “Company“) announced that Nevada County (the “County”), Rise, and the Superior Court of California for the County of Nevada (the “Court”) agreed to a schedule that anticipated that oral arguments concerning

Burcon Increases Non-Brokered Private Placement of Convertible Debentures to $6.9 Million

Vancouver, British Columbia–(Newsfile Corp. – January 9, 2026) – Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (“Burcon” or the “Company“), a global technology leader in plant-based protein innovation, is pleased to announce that, in response to strong demand, it has increased the size of its previously announced non-brokered private placement (the “Private Placement”) of convertible debentures (the

Antimony Resources Corp. (ATMY) (ATMYF) (K8J0) Reports More Massive Antimony-Bearing Stibnite (“Sb”) of 8.48% Sb over 3.0 Meters and 2.07% Sb over 27.05 Meters

Vancouver, British Columbia–(Newsfile Corp. – January 9, 2026) – Antimony Resources Corp. (CSE: ATMY) (OTCQB: ATMYF) (FSE: K8J0) (the “Company” or “Antimony Resources” or “ATMY”) is pleased to present the latest set of High-Grade antimony (Sb) assays from the Bald Hill Antimony Project in New Brunswick, Canada. Assays for Drill Holes BH-25-17 to BH-25-22 are

Hurco Reports Fourth Quarter and Full Year Results for Fiscal Year 2025

(NASDAQ:HURC), INDIANAPOLIS, Jan. 09, 2026 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2025. Hurco recorded a net loss of $3,041,000, or $0.47 per diluted share, for the fourth quarter of fiscal year 2025, compared to a net loss of $1,442,000,

Attindas Hygiene Partners Expands European Position with Key Acquisition

RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners' growth strategy realized an important step forward today with its acquisition of Societa Italiana Lavorazione Cellulosa (SILC S.p.A.). Attindas executed a share purchase agreement with SILC, acquiring all shares of the 53-year-old, family-owned company. SILC S.p.A. serves customers throughout Europe with high-quality, absorbent hygiene

Peer-reviewed study demonstrates LEON’s FR-JET(R) modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity

PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) — A new study published in Pharmaceutics (https://doi.org/10.3390/pharmaceutics18010050) shows that LEON's FR-JET(R) modular mixer addresses key manufacturing challenges by enabling the production of highly concentrated lipid nanoparticles (LNPs). The study demonstrates that LNP formulation at significantly higher lipid mixture concentrations, beyond those currently reported in the

Scroll to Top